Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
The objective-response rate and the progression-free survival among patients with advanced melanoma who had not previously received treatment were significantly greater with niv...
The objective-response rate and the progression-free survival among patients with advanced melanoma who had not previously received treatment were significantly greater with niv...
Larotrectinib had marked and durable antitumor activity in patients with TRK fusion-positive cancer, regardless of the age of the patient or of the tumor type. (Funded by Loxo O...
h-index: Number of publications with at least h citations each.